Elilly在印度投资1B美元, 以扩大糖尿病、肥胖症及其他关键药物的制造, Eli Lilly invests $1B in India to expand manufacturing of diabetes, obesity, and other key drugs, boosting supply and access.

Elilly计划在印度投资10亿美元,扩大治疗糖尿病、肥胖症、阿尔茨海默氏症、癌症和自免疫疾病的关键药物的合同制造,在海得拉巴建立新的质量和制造中心。 Eli Lilly plans a $1 billion investment in India to expand contract manufacturing for key drugs treating diabetes, obesity, Alzheimer’s, cancer, and autoimmune diseases, establishing a new quality and manufacturing hub in Hyderabad. 此举是全球更广泛扩张的一部分,它支持增加药品的供应和获取机会,利用印度熟练劳动力和合同制造专门知识。 The move, part of a broader global expansion, supports increased supply and access to medicines, leveraging India’s skilled workforce and contract manufacturing expertise. 工程、科学和质量角色的征聘将立即开始。 Recruitment for engineering, scientific, and quality roles will begin immediately. 这项投资是在索马鲁肽专利明年到期后预计来自印度仿制药的竞争加剧之际进行的，并且礼来公司将提高美国产量以应对新关税。 The investment comes amid rising competition from Indian generics expected after semaglutide patents expire next year and as Lilly boosts U.S. production in response to new tariffs.